PTSD drug shows promise in Long-Term Follow-Up

NCT ID NCT06237426

First seen Jan 10, 2026 · Last updated Apr 29, 2026 · Updated 17 times

Summary

This study looks at the long-term safety and effectiveness of methylone (TSND-201) for people with PTSD. It follows 44 adults who completed a previous methylone trial for up to 52 weeks. Researchers check PTSD symptoms monthly and offer additional treatment if symptoms return.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for POST-TRAUMATIC STRESS DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Cambridgeshire and Peterborough NHS Foundation Trust

    Cambridge, England, United Kingdom

  • Cedar Clinical Research, Inc

    Draper, Utah, 84020, United States

  • Clerkenwell Health

    London, United Kingdom

  • Kings College

    London, United Kingdom

  • La Nua Mental Health Centre

    Galway, Ireland

  • Mirabilis Health

    Belfast, Northern Ireland, United Kingdom

  • Mountain View Clinical Research

    Denver, Colorado, 80209, United States

  • NHS Greater Glasgow and Clyde

    Glasgow, Scotland, United Kingdom

  • Sunstone Medical

    Rockville, Maryland, 20850, United States

Conditions

Explore the condition pages connected to this study.